Adding TACE to Lenvatinib Improves Survival in Liver Cancer

Transarterial chemoembolization (TACE) added onto lenvatinib is a new first-line option for patients with advanced liver cancer, say LAUNCH trialists.
Medscape Medical News

source https://www.medscape.com/viewarticle/967184?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?